P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability
Keywords: ABC; ATP-binding cassette; ALK; anaplastic lymphoma kinase; ANOVA; analysis of variance; AUC; area under plasma concentration-time curve; BBB; blood-brain barrier; BCRP; breast cancer resistance protein; BTB; blood-testis barrier; Cbrain; brain concentrat